BS_C05FKR8X
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 7.030223390275952
- age_years
- 16.51
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.458
- NOTCH_SIGNALING+0.368
- G2M_CHECKPOINT+0.357
- CHOLESTEROL_HOMEOSTASIS+0.304
- E2F_TARGETS+0.275
- DNA_REPAIR+0.231
- MYC_TARGETS_V2+0.221
- HEDGEHOG_SIGNALING+0.220
- APICAL_JUNCTION+0.145
- ANGIOGENESIS+0.138
Top 10 suppressed
- PROTEIN_SECRETION-0.446
- INTERFERON_GAMMA_RESPONSE-0.333
- ALLOGRAFT_REJECTION-0.322
- ANDROGEN_RESPONSE-0.309
- INTERFERON_ALPHA_RESPONSE-0.299
- IL6_JAK_STAT3_SIGNALING-0.280
- KRAS_SIGNALING_UP-0.280
- INFLAMMATORY_RESPONSE-0.271
- OXIDATIVE_PHOSPHORYLATION-0.270
- COMPLEMENT-0.255
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_C05FKR8X | EPN | Supratentorial EPN | 0.917 |
| 2 | SJEPD036_D.RNA-Seq | EPN | Supratentorial EPN | 0.840 |
| 3 | SRR12475126 | — | — | 0.833 |
| 4 | BS_NB42PWZN | Supratentorial Ependymoma | — | 0.812 |
| 5 | ERR2598071 | fetal | fetal | 0.798 |
| 6 | SRR17866843 | — | — | 0.793 |
| 7 | MDT-AP-0831 | Med | Medulloblastoma | 0.781 |
| 8 | BS_7WNSZNE3 | DNET | — | 0.777 |
| 9 | SRR11296886 | — | — | 0.770 |
| 10 | MNG1255 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.458 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.368 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.357 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.304 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.275 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.231 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.221 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.145 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.138 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.125 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.119 | Inavolisib | — uncovered |
| HYPOXIA | 0.104 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.088 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.058 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.029 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.007 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.006 | Remibrutinib | — uncovered |